IOL Chemicals and Pharmaceuticals Limited
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.
What IOL files
- Others59
- Investor Meet36
- Important24
- Updates24
- Board Meeting9
- PPTs6
IOL Chemicals & Pharmaceuticals (IOLCP) reported strong Q4 & FY26 financial results. Q4 revenue grew 39.8% YoY to ₹619.5 Cr, with PAT up 68.2% YoY to ₹53.2 Cr. For FY26, revenue increased 11.5% YoY to ₹2,319.1 Cr and PAT rose 36.4% YoY to ₹137.7 Cr. Both Pharmaceutical (60% of revenue)...
IOL Chemicals & Pharmaceuticals (IOLCP) posted solid Q3 FY26 results. 💪 Revenue grew 10.9% YoY to ₹580.4 Cr, with Profit Before Tax (PBT) surging 39.3% to ₹38.8 Cr. EBITDA increased 22.8% to ₹62.6 Cr. The Pharmaceuticals segment showed strong performance, contributing significantly to 9-month revenue. Strategy focuses on diversifying beyond...
IOL Chemicals & Pharma delivered strong Q2 & H1 FY26 financial results. Q2 revenue rose 7.9% YoY to ₹567.5 Cr, with profit after tax jumping 56.7% YoY to ₹30.0 Cr. H1 saw revenue grow 8.9% YoY to ₹1,119.2 Cr and profit up 31.0% YoY to ₹64.0 Cr. The Pharmaceuticals segment...
**1. Financial Highlights:** IOLCP's Q1 FY26 financial results show Revenue from Operations reached ₹551.7 Cr (+9.8% YoY) and Profit After Tax (PAT) hit ₹34.0 Cr (+14.4% YoY). The company reported an EBITDA margin of 12.4%, PAT margin of 6.1%, and a healthy 0.07 Debt to Equity Ratio. **2. Strategic Initiatives...
**Financial Highlights**: For Q3 FY2025, IOL Chemicals and Pharmaceuticals reported total income of ₹527 Cr, slightly down from ₹528.8 Cr YoY. EBITDA for the quarter was ₹51 Cr, resulting in an EBITDA margin of 9.7%. Profit After Tax (PAT) decreased to ₹21 Cr, with a PAT margin of 3.9%. For...